Literature DB >> 11499867

Accelerated turnover of metaphyseal trabecular bone in mice overexpressing cathepsin K.

R Kiviranta1, J Morko, H Uusitalo, H T Aro, E Vuorio, J Rantakokko.   

Abstract

This study is based on a hypothesis that overexpression of an osteoclast enzyme, cathepsin K, causes an imbalance in bone remodeling toward bone loss. The hypothesis was tested in transgenic (TG) mice harboring additional copies of the murine cathepsin K gene (Ctsk) identifiable by a silent mutation engineered into the construct. For this study, three TG mouse lines harboring 3-25 copies of the transgene were selected. Tissue specificity of transgene expression was determined by Northern analysis, which revealed up to 6-fold increases in the levels of cathepsin K messenger RNA (mRNA) in calvarial and long bone samples of the three TG lines. No changes were seen in the mRNA levels of other osteoclast enzymes, indicating that the increase in cathepsin K mRNA was not a reflection of activation of all osteoclast enzymes. Immunohistochemistry confirmed that cathepsin K expression in the TG mice was confined to osteoclasts and chondroclasts. Histomorphometry revealed a significantly decreased trabecular bone volume (BV), but, surprisingly, also a marked increase in the number of osteoblasts, the rate of bone turnover, and the amount of mineralizing surface (MS). However, monitoring of bone density in the proximal tibias of the TG mice with peripheral quantitative computed tomography (pQCT) failed to reveal statistically significant changes in bone density. Similarly, no statistically significant alterations were observed in biomechanical testing at the age of 7 months. The increases in parameters of bone formation triggered by increased cathepsin K expression is an example of the tight coupling of bone resorption and formation during the bone-remodeling cycle.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11499867     DOI: 10.1359/jbmr.2001.16.8.1444

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  30 in total

1.  Low dose of propranolol down-modulates bone resorption by inhibiting inflammation and osteoclast differentiation.

Authors:  W F Rodrigues; M F M Madeira; T A da Silva; J T Clemente-Napimoga; C B Miguel; V J Dias-da-Silva; O Barbosa-Neto; A H Lopes; M H Napimoga
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

2.  Macrophage cathepsin K promotes prostate tumor progression in bone.

Authors:  M K Herroon; E Rajagurubandara; D L Rudy; A Chalasani; A L Hardaway; I Podgorski
Journal:  Oncogene       Date:  2012-05-21       Impact factor: 9.867

Review 3.  Current, new and future treatments of osteoporosis.

Authors:  Pooneh Salari Sharif; Mohammad Abdollahi; Bagher Larijani
Journal:  Rheumatol Int       Date:  2010-07-30       Impact factor: 2.631

4.  Lactating Ctcgrp nulls lose twice the normal bone mineral content due to fewer osteoblasts and more osteoclasts, whereas bone mass is fully restored after weaning in association with up-regulation of Wnt signaling and other novel genes.

Authors:  Jillian N Collins; Beth J Kirby; Janine P Woodrow; Robert F Gagel; Clifford J Rosen; Natalie A Sims; Christopher S Kovacs
Journal:  Endocrinology       Date:  2013-03-05       Impact factor: 4.736

5.  Therapeutic inhibition of cathepsin K-reducing bone resorption while maintaining bone formation.

Authors:  Le T Duong
Journal:  Bonekey Rep       Date:  2012-05-02

Review 6.  Osteoblast-osteoclast interactions.

Authors:  Xiao Chen; Zhongqiu Wang; Na Duan; Guoying Zhu; Edward M Schwarz; Chao Xie
Journal:  Connect Tissue Res       Date:  2017-03-21       Impact factor: 3.417

7.  In vitro method for the screening and monitoring of estrogen-deficiency osteoporosis by targeting peripheral circulating monocytes.

Authors:  Francesca Salamanna; Melania Maglio; Gianluca Giavaresi; Stefania Pagani; Roberto Giardino; Milena Fini
Journal:  Age (Dordr)       Date:  2015-08-07

8.  Cathepsin K is the principal protease in giant cell tumor of bone.

Authors:  Jan H N Lindeman; Roeland Hanemaaijer; Adri Mulder; P D Sander Dijkstra; Károly Szuhai; Dieter Bromme; Jan H Verheijen; Pancras C W Hogendoorn
Journal:  Am J Pathol       Date:  2004-08       Impact factor: 4.307

9.  Bone marrow-derived cathepsin K cleaves SPARC in bone metastasis.

Authors:  Izabela Podgorski; Bruce E Linebaugh; Jennifer E Koblinski; Deborah L Rudy; Mackenzie K Herroon; Mary B Olive; Bonnie F Sloane
Journal:  Am J Pathol       Date:  2009-08-21       Impact factor: 4.307

10.  A broad survey of cathepsin K immunoreactivity in human neoplasms.

Authors:  Gang Zheng; Guido Martignoni; Cristina Antonescu; Elizabeth Montgomery; Charles Eberhart; George Netto; Janis Taube; William Westra; Jonathan I Epstein; Tamara Lotan; Anirban Maitra; Edward Gabrielson; Michael Torbenson; Christine Iacobuzio-Donahue; Angelo Demarzo; Ie Ming Shih; Peter Illei; T C Wu; Pedram Argani
Journal:  Am J Clin Pathol       Date:  2013-02       Impact factor: 2.493

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.